Insight in Quinazoline-based HDAC Inhibitors as Anti-cancer Agents

Area of Science:

• Medicinal Chemistry
• Oncology
• Pharmacology

Background:

• Cancer is a leading global cause of death with limited effective treatments.
• Chemotherapy improves survival but causes significant side effects.
• Developing potent anticancer agents with minimal toxicity remains a critical challenge.

Purpose of the Study:

• To review the potential of quinazoline derivatives in developing novel anticancer therapeutics.
• To explore quinazolines as inhibitors of histone deacetylases (HDACs) for cancer treatment.

Main Methods:

• Literature review of existing studies on quinazoline-based anticancer agents.
• Analysis of structure-activity relationships of quinazolines targeting HDACs.
• Discussion of the therapeutic potential and challenges of quinazoline-HDAC inhibitors.

Main Results:

• Quinazoline scaffolds are versatile and have been incorporated into various antitumor agents.
• Several quinazoline derivatives exhibit potent anticancer activity by inhibiting HDACs.
• These compounds offer a promising avenue for targeted cancer therapy.

Conclusions:

• Quinazolines represent a valuable class of compounds for the development of next-generation anticancer drugs.
• Targeting HDACs with quinazoline-based inhibitors is a viable strategy to combat cancer.
• Further research is warranted to optimize these agents for clinical application.